An immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic phar-maceutical composition comprising at least an antigen and the above-mentioned immune enhancers is disclosed. A preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition are also disclosed. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

A method for treating or reducing the incidence of recurrence of cancer, benign tumors, or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient.

Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

A screening method of individualized tumor neoantigen peptide and a vaccine preparation thereof are provided. The screening method includes: Step 1, collecting and collating variable information for mutation producing a neoantigen and an antigenic peptide; Step 2, calculating according to a formula to obtain a score of each antigenic peptide; Step 3, arranging the antigen peptides in a descending order according to iNeo_Score, and selecting the antigen peptides from top to bottom successively; Step 4, continuing to select an antigenic peptide until enough candidate antigenic peptides are obtained or all of candidate antigenic peptides are selected so as to obtain screened antigenic peptides; and Step 5, grouping the screened antigen peptides into preparation groups. The designed individualized tumor neoantigen peptide is screened and prepared into a preparation in the disclosure, which includes screened antigen peptide, inorganic salt and an excipient. The preparation can be made into small-volume injection.

The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.

The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.

This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.

The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods comprising administering to a subject in need thereof for the treatment of cancer a NKG2A neutralizing agent, a PD-1 neutralizing agent, a chemotherapy agent, and a VEGF neutralizing agent or an EGFR neutralizing agent.

The present invention identifies the influence of the TGFβ/Smad3/SMO molecular mechanism in cancer cells and elucidates that a high expression level of SMO is associated with the overall survival rate of cancer patients, demonstrating that SMO is a potential prognostic marker for cancer. The present invention relates to a specific epitope of SMO as an antigen and an antibody or a fragment thereof recognizing and binding specifically to the epitope. Therefore, the antibody of the present invention is expected to be useful as a therapeutic agent for SMO-related cancers.